Hook & thesis
Mirum Pharmaceuticals is no longer a one-drug story. The company has parlayed Livmarli (marketed as a core revenue driver) into a broader liver-disease platform and recently absorbed a meaningful asset via a $620 million acquisition, giving it revenue scale and pipeline optionality. The market has rewarded that progress: MIRM is trading near its 52-week high at $125.72 and the technicals show bullish momentum, but the valuation is full. For tactical traders willing to accept elevated risk, I like a mid-term long to ride further multiple expansion and catalyst-driven upside.
The trade is not a passive “buy and forget.” Mirum combines strong top-line growth (reported 56.8% year-over-year revenue growth through nine months) with improving profitability signals (profitability noted in Q3 2025) and attractive balance-sheet ratios (current ratio ~2.09, quick ratio ~1.99). That sets up a scenario where commercial execution and successful integration of the Bluejay asset can drive upside — while a lofty price-to-sales and negative EPS warrant a tight stop and clear targets.
Business snapshot - what Mirum does and why the market should care
Mirum is a late-stage biopharma focused on debilitating liver diseases. Its commercial and pipeline lineup includes Livmarli (driving current sales), Cholbam, and clinical-stage assets such as volixibat and MRM-3379. The company’s strategy is to grow via commercialization of existing approved products and broaden indications through clinical readouts and M&A.
Why the market cares: liver-disease indications (including rare cholestatic diseases and NASH-related endpoints) carry outsized pricing power and extended patient lifecycles when a therapy meaningfully shifts clinical outcomes. Mirum already shows commercial traction: meaningful year-over-year revenue growth (56.8% through nine months) and reported profitability in Q3 2025, albeit with guidance pointing to a slower 2026 growth rate (management guided to ~23.1% sales growth for 2026 vs 54.4% in 2025). The ability to sustain >20% growth while integrating acquisitions is the core fundamental driver for multiple expansion from here.
Numbers that matter (select metrics)
| Metric | Value |
|---|---|
| Current price | $125.72 |
| Market cap | $7.66B |
| 52-week range | $49.01 - $125.75 (high on 07/02/2026) |
| Price-to-sales | 13.45x |
| Price-to-book | 31.58x |
| EPS (TTM) | -$13.10 |
| Enterprise value | $7.64B |
| Free cash flow | -$172.6M |
| Liquidity ratios | Current 2.09x, Quick 1.99x, Cash 1.19x |
Valuation framing
At roughly $7.66 billion market cap and an enterprise value near $7.64 billion, Mirum is being valued like a scaled commercial biotech. The stock’s price-to-sales of ~13.5x and P/B above 30x reflect investor expectations for continued strong revenue growth and steadying profitability. That is a premium multiple — justified only if Livmarli continues to expand, the Bluejay acquisition meaningfully lifts revenue/profitability, and clinical assets deliver positive readouts that expand addressable markets.
Qualitatively, this is a commercial-stage biotech that has moved from development-risk to execution-risk. Historically, investors pay up for durable commercial franchises in orphan indications; Mirum is priced for success. That creates the trade setup: if the company executes near-term commercial and integration milestones, the stock can re-rate higher. If these fail, downside could be severe given the stretched multiples.
Catalysts to watch (2-5)
- Commercial cadence & sales releases — incremental Livmarli revenue beats or upward revisions to 2026 revenue guidance would validate current multiples.
- Integration updates on the $620M Bluejay acquisition — clear cost synergies or early revenue contribution would materially de-risk the acquisition premium.
- Clinical readouts for pipeline assets (volixibat, MRM-3379) — positive data would expand the addressable market and justify premium valuation.
- Regulatory decisions in international markets or label expansions for core products.
- Short-covering events — short interest is sizable and episodic; a squeeze around a positive catalyst can accelerate rallies.
Technicals & market structure
Momentum indicators are constructive: the 10-, 20-, and 50-day SMAs are all below the current price ($116.81, $107.03, and $102.51 respectively), RSI sits at ~72.5 indicating short-term overbought conditions, and MACD shows bullish momentum. Average daily volume has been elevated versus historical norms; short-volume data shows persistent heavy short activity — days-to-cover has bounced in the ~8-14 range over recent settlement windows. That combination supports a momentum-driven mid-term trade but also elevates volatility risk.
Trade plan (exacts and timeframe)
Stance: Long.
Entry price: $125.72 (current market level).
Target price: $165.00.
Stop loss: $105.00.
Horizon: mid term (45 trading days). This timeframe captures near-term commercial updates, initial integration commentary on the acquisition, and any early clinical readout noise that could move the stock. The mid-term horizon balances the momentum setup with the operational calendar expected to produce confirmatory news within ~2 months.
Rationale: Entry near $125 captures momentum after a breakout toward a 52-week high. The $165 target implies about 31% upside — reasonable if Mirum prints another beat or provides encouraging acquisition/integration milestones. The $105 stop sits below the 50-day SMA area (~$102.50) and provides room for normal biotech volatility while limiting downside to roughly 16% from entry.
Risk profile & sizing guidance
This is a high-risk trade. Position sizing should reflect that: consider risking no more than 1-2% of portfolio equity on this single trade given the stock’s valuation, negative EPS, and history of volatile moves. The pair of stretched valuation metrics (P/S ~13.5x; P/B >30x) and negative free cash flow make the company dependent on continued revenue growth and successful M&A integration for near-term multiple support.
Risks and counterarguments
- Valuation risk: The stock is priced for perfection. Any miss in sales guidance or integration costs from the $620M acquisition could trigger a sharp de-rate.
- Clinical and regulatory risk: Pipeline readouts can disappoint. Negative data for volixibat or other candidates would compress the multiple quickly.
- Execution risk on integration: The Bluejay purchase is sizable relative to the firm’s prior scale; failure to capture synergies or higher near-term spend could erase profit progress.
- Market / technical risk: RSI is overbought and short interest is material — coordinated shorting or broad biotech weakness could produce a fast pullback.
- Liquidity & macro risk: A wider market sell-off or a rotation out of high-multiple healthcare names would disproportionately hurt Mirum.
Counterargument: One could argue Mirum is already fully valued and that the business will struggle to sustain margins after the acquisition. The company’s P/S and P/B signal that much of the upside is priced in; conservative investors might wait for a pullback into the $90-$110 range or for unequivocal evidence the acquisition is accretive to sales and margins before committing capital. That is a valid, risk-averse approach.
What would change my mind
I would abandon the long thesis if Mirum: (a) cuts 2026 revenue guidance materially below the current ~23% growth expectation, (b) reports acquisition-related charges or integration guidance that materially widen losses or cash-burn beyond current expectations, or (c) posts clinical readouts that weaken the pipeline’s commercial potential. Conversely, sustained upward revisions to guidance, clear accretion from the acquisition, or positive phase readouts would reinforce the bullish case and justify extending the horizon beyond 45 trading days.
Conclusion
Mirum sits at the intersection of commercial execution and pipeline optionality. The company has moved into a new phase — broader product mix, a material acquisition, and the potential for more durable profitability. That combination can justify premium multiples, but it also creates binary outcomes. For traders who can tolerate volatility and size positions tightly, a mid-term long at $125.72 with a $105 stop and a $165 target is a reasonable way to bet on continued commercial momentum and successful integration. If you prefer lower-risk entry points, wait for a consolidation into the $100-$110 zone or clearer acquisition accretion metrics.